Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: Implications for vascular disease and therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 2, 2000, Pages 309-316

  Sata, Masataka ^a,b   Suhara, Toshimitsu ^a   Walsh, Kenneth ^a,c  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Apoptosis; Endothelial cells; Fas; Smooth muscle cells

Indexed keywords

CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

EID: 0033980167     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.2.309     Document Type: Article

References (46)

1. Nagata S, Golstein P. The Fas death factor. Science. 1995;267: 1449-1456.
2. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
3. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
4. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role of CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
5. Dockrell D, Badley A, Villacian J, Heppelmann C, Algeciras A, Ziesmer S, Yagita H, Lynch D, Roche P, Leibson P, Paya C. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest. 1998;101:2394-2405.
6. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996;157:2909-2915.
7. Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:1682-1689.
8. Fukuo K, Nakahashi T, Nomura S, Hata S, Suhara T, Shimizu M, Tamatani M, Morimoto S, Kitamura Y, Ogihara T. Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Gerontology. 1997;43:35-42.
9. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177-186.
10. Geng Y-J, Henderson LE, Levesque EB, Muszynzki M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2200-2208.
11. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest. 1996;74:921-931.
12. Sata M, Walsh K. TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med. 1998; 4:415-420.
13. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A. 1998;95:1213-1217.
14. Richardson BC, Lalwani ND, Johnson KJ, Marks RM. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol. 1994;24:2640-2645.
15. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998;282:290-293.
16. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension. 1996;27:823-826.
17. Suhara T, Fukuo K, Sugimoto T, Morimoto S, Nakahashi T, Hata S, Shimizu M, Ogihara T. Hydrogen peroxide induces up-regulation of Fas in human endothelial cells. J Immunol. 1998;160:4042-4047.
18. Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY, Walsh K. Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999;99: 1776-1779.
19. Biancone L, Martino AD, Orlandi V, Conaldi PG, Toniolo A, Camussi G. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med. 1997;186:147-152.
20. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.
21. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050.
22. Smith D, Sieg S, Kaplan D. Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol. 1998;160: 4159-4160.
23. Stokes TA, Rymaszewski M, Arscott PL, Wang SH, Bretz JD, Bartron J, Baker JRJ. Technical comments: constitutive expression of FasL in thyrocytes. Science. 1998;279:2015a.
24. Fiedler P, Schaetzlein CE, Eibel H. Technical comments: constitutive expression of FasL in thyrocytes. Science. 1998;279:2015a.
25. Papoff G, Stassi G, Maria RD, Giordano C, Galluzzo A, Bagnasco M, Ruberti G, Testi R. Technical comments: constitutive expression of FasL in thyrocytes. Science. 1998;279:2015a.
26. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52: 2757-2764.
27. Pickering JG, Weir L, Rosenfield K, Stetz J, Jekanowski J, Isner JM. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J Am Coll Cardiol. 1992; 20:1430-1439.
28. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169:1747-1756.
29. Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sukhatme VP, Libermann TA. Adenovirus mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo infected pancreatic islet allografts and isografts. Hum Gene Ther. 1997; 8:955-963.
30. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med. 1999;5:90-96.
31. Li JH, Rosen D, Ronen D, Behrens CK, Krammer PH, Clarke WR, Berke G. The regulation of CD95 ligand expression and function in CTL. J Immunol. 1998;161:3943-3949.
32. Giordano C, Stassi G, DeMaria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275:960-963.
33. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WSM. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 1998;392:726-729.
34. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation. 1997;95:1505-1514.
35. Perlman H, Sata M, Le Roux A, Sedlak TW, Branellec D, Walsh K. Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity. EMBO J. 1998;17: 3576-3586.
36. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050.
37. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-of-induced cell death. Science. 1996;274:782-784.
38. Wang C-Y, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274: 784-787.
39. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schroter M, Burns K, Mattmann C, Rimoldi D, French L, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
40. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J Biol Chem. 1997;272:17255-17257.
41. Srinivasula SM, Ahmad M, Otilie S, Bullrich F, Banks S, Fernandes-Alnemri T, Croce CM, Litwack G, Tomaselli KJ, Armstrong RC, Alnemri ES. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem. 1997;272:18542-18545.
42. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the downregulation of the cellular caspase inhibitor FLIP. J Biol Chem. 1998;273:33103-33106.
43. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19:19-25.
44. Russel PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. Am J Pathol 1994;144:260-274.
45. Isik FF, McDonald TO, Ferguson M, Yamanaka E, Gordon D. Transplant arteriosclerosis in a rat aortic model. Am J Pathol. 1992; 141:1139-1149.
46. McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, Green DR. The end of the cell line: methods for the study of apoptosis in vitro. In: Schwartz LM, Osborne BA, eds. Cell Death. San Diego, Calif: Academic Press Inc; 1995:153-185.